Mar 3, 2014 9:35am EST Tonix Pharmaceuticals Completes Pre-IND Meeting With FDA on TNX-201 for Episodic Tension-Type Headache: Clinical Development to Begin in 4Q 2014
Jan 29, 2014 11:15am EST Tonix Pharmaceuticals Announces Closing of $43.5 Million Public Offering of Common Stock
Jan 24, 2014 8:20am EST Tonix Pharmaceuticals Prices Underwritten Public Offering Raising $43.5 Million
Dec 10, 2013 8:40am EST Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study